Botulinum Toxin

Kim, Won Oak; Kil, Hae Keum; Yoon, Kyung Bong; Noh, Ko Un

doi:10.1111/j.1524-4725.2009.01140.x

Cited by 30 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsiding of treatment effect is another disadvantage. [9] So this option should be regarded as a temporary approach for symptom-relief, not a definitive treatment option.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of compensatory hyperhidrosis of the trunk with radiofrequency ablation

Deniz

Kavakli

Çaylak

et al. 2015

Agri

View full text Add to dashboard Cite

SummaryObjectives: Although Endoscopic Thoracic Sympathectomy is a widely accepted treatment method for patients with palmar hyperhidrosis, compensatory hyperhidrosis of the trunk remains a challenging side effect of the procedure. No satisfactory treatment options for this side effect were available until now. In this study, we aimed to define a new procedure for the treatment of compensatory hyperhidrosis of the trunk. Methods: A total of 10 patients admitted our institution for the treatment of compensatory hyperhidrosis of the trunk were enrolled in the study between November 2010 and January 2012 in a prospective manner. Sympathetic blockage was achieved via radiofrequency thermo-ablation technique. The results of treatment were evaluated via telephone calls. Results: Ten patients (2 females, 8 males) underwent radiofrequency thermo-ablation of T6 sympathetic ganglion for compensatory hyperhidrosis of the trunk. The mean age was 29.2 years and the median duration of symptom was 10.5 months. The median follow-up period was 14 months. Six of ten patients (60%) were treated successfully. There was no procedure related complication. Conclusion:The radiofrequency treatment for patients with compensatory hyperhidrosis of the trunk is an alternative option with promising results.

show abstract

“…Subsiding of treatment effect is another disadvantage. [9] So this option should be regarded as a temporary approach for symptom-relief, not a definitive treatment option.…”

Section: Resultsmentioning

confidence: 99%

“…However, this treatment option does not provide a permanent relief. [9] Proper management of CH following sympathectomy is of paramount importance. In this study, we aimed to present a new treatment option for CH.…”

Section: Introductionmentioning

confidence: 99%

Treatment of compensatory hyperhidrosis of the trunk with radiofrequency ablation

Deniz

Kavakli

Çaylak

et al. 2015

Agri

View full text Add to dashboard Cite

show abstract

“…2,3 Botulinum toxin A has been FDA approved for axillary HH treatment with a well established efficacy by blocking acetylcholine release at the neuromuscular junction from cholinergic fibers to inhibit sweat production from eccrine glands. 4 It has demonstrated good efficacy in patients with facial HH. 5 Glycopyrrolate is one of the most common anticholinergics used to reduce sweating by blocking acetylcholine effect at parasympathetic sites with fewer central side effects than other agents because it does not cross the blood-brain barrier.…”

mentioning

confidence: 99%

“…Botulinum toxin A has been FDA approved for axillary HH treatment with a well established efficacy by blocking acetylcholine release at the neuromuscular junction from cholinergic fibers to inhibit sweat production from eccrine glands. 4 It has demonstrated good efficacy in patients with facial HH. 5…”

mentioning

confidence: 99%

Intradermal Botulinum Toxin A Injection Versus Topical 2% Glycopyrrolate for the Treatment of Primary Facial Hyperhidrosis: A Pilot Study and Review of Literature

Nofal

Salem

Khashaba

2022

View full text Add to dashboard Cite

BACKGROUNDFacial hyperhidrosis (HH), a common problem with both cosmetic and psychological impact, interferes with quality of life. Wide range of treatment options is available for HH. Finding the most effective and yet a safe, tolerable option is the main target.OBJECTIVETo evaluate and compare clinical efficacy, safety, and tolerability of topical 2% glycopyrrolate versus intradermal Botulinum toxin A injection in facial HH treatment.MATERIALS AND METHODSTwenty-four patients with primary facial HH were randomly divided into 2 equal groups: Group A included patients treated by intradermal Botulinum toxin A injection and Group B included patients treated by topical glycopyrrolate gel 2%. Starch iodine test was performed before and after treatment to assess response, along with Hyperhidrosis Disease Severity Scale, Dermatology Life Quality Index (DLQI), and patient satisfaction.RESULTSBoth modalities showed complete response in 75% of cases with a longer duration of action in botulinum toxin group up to 6 months. Side effects were minor and temporary. Both Hyperhidrosis Disease Severity Scale and DLQI showed statistically significant improvement after treatment.CONCLUSIONTopical glycopyrrolate 2% showed comparable results to Botulinum toxin A in facial HH treatment with faster onset but shorter duration of action.

show abstract

Primary Focal Palm, Sole, Craniofacial, and Compensatory Hyperhidrosis

Glaser

Mattox

2017

Botulinum Toxins

View full text Add to dashboard Cite

Botulinum Toxin

Abstract: BTX-A injection was a well-tolerated, effective, and safe method for treating severe truncal CH, although the considerable cost and limited duration of the treatment effects were major disadvantages.

Cited by 30 publications

References 20 publications

Treatment of compensatory hyperhidrosis of the trunk with radiofrequency ablation

Treatment of compensatory hyperhidrosis of the trunk with radiofrequency ablation

Intradermal Botulinum Toxin A Injection Versus Topical 2% Glycopyrrolate for the Treatment of Primary Facial Hyperhidrosis: A Pilot Study and Review of Literature

Primary Focal Palm, Sole, Craniofacial, and Compensatory Hyperhidrosis

Contact Info

Product

Resources

About